Sign In
Buy VTRS
$17.56
-0.200 (-1.13%)
At Close: Jul 31, 2026
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
10:00am, Friday, 01'st Aug 2025
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VT
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
10:51am, Monday, 21'st Jul 2025
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
02:17pm, Friday, 18'th Jul 2025
As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the effic
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
08:47am, Friday, 18'th Jul 2025
The pharmaceutical company says its eye inflammation treatment didn't meet its target.
Viatris eye therapy fails to meet late-stage trial goal
07:07am, Friday, 18'th Jul 2025
Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
06:59am, Friday, 18'th Jul 2025
PITTSBURGH , July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate th
Viatris: A Contrarian Bet With Virtually No Downside
03:19am, Wednesday, 16'th Jul 2025
Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, divid
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
06:55am, Thursday, 26'th Jun 2025
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinica
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
04:30pm, Thursday, 12'th Jun 2025
PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.
Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm
10:41am, Tuesday, 10'th Jun 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. (NASDAQ: VTRS) breached their fi
Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
01:06pm, Monday, 09'th Jun 2025
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
10:31am, Monday, 09'th Jun 2025
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript
11:04am, Thursday, 05'th Jun 2025
Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities betwee
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
01:00pm, Tuesday, 03'rd Jun 2025
LOS ANGELES--(BUSINESS WIRE)--VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm.
